AI-Rad CompanionProviding multi-modality imaging decision support
The AI-Rad Companion, our family of AI-powered, augmented workflow solutions, helps you to reduce the burden of basic repetitive tasks and may increase your diagnostic precision when interpreting medical images.
Its solutions provide automatic post-processing of imaging datasets through our AI-powered algorithms. The automation of routine workflows with repetitive tasks and high case volumes helps you to ease your daily workflow – so that you can focus on more critical issues.
Up-to-date algorithms and scalable offerings
Our state-of-the-art algorithms will be automatically distributed to you as a user as soon as they are officially released and made available. Once the images are post-processed by the AI-Rad Companion, it supports your interpretation of the data by automatically providing results of its analysis to you for review, confirmation and possible inclusion in the final report or care pathway – to raise your precision and ensure high quality outcome in diagnostic decision-making.
All our AI-Rad Companion extensions are deployed via the teamplay digital health platform. This approach eases regular updates as well as upgrade processes and facilitates the integration of new offerings into the existing IT environment.
The AI-Rad Companion family is growing
AI-Rad Companion Brain MR1 – your imaging decision support aide for morphometry analysis
This extension is a post-processing image analysis software that assists clinicians in viewing, analyzing, and evaluating MR brain images as a diagnostic aid. AI-Rad Companion brings value to the interpretation process in supporting the clinician by automatic segmentation and analysis of individual brain structures. The volume of each of these structures will be compared to a normative database and results will be offered in graphics and numerical values.
AI-Rad Companion Chest CT1 – your imaging decision support aide for chest CT interpretation
This includes the ability to provide lung lobe segmentation, lung lesion detection and measurements, heart segmentation and calcium detection, aorta segmentation and diameter measurements, as well as vertebra body segmentation and measurement. With the current COVID-19 pandemic, users can also take advantage of the pulmonary density results, which identifies areas of increased density, which may be used to identify pneumonia related to COVID-19.
AI-Rad Companion Chest X-ray2 – your aide for chest X-ray interpretation
The application helps to detect radiographic findings on Chest X-ray images with the use of AI. The algorithm can characterize and highlight the findings of pulmonary lesions, pleural effusion, pneumothorax, consolidation and atelectasis. The output from the AI-Rad Companion Chest X-ray is used in concurrent-read mode to support radiologists in their differential diagnosis and clinical decision-making.
AI-Rad Companion Prostate MR1 – your aide for biopsy support
The application supports in annotating images of the prostate gland for targeted MR/US-fusion biopsies and seamless information transfer to the urologist. Efficiency is gained as the AI-Rad Companion automatically segments the prostate gland, typically a tedious and time-consuming manual task. The radiologist can additionally mark potential targets for biopsy, reducing the risk for information loss. This may foster collaboration between the radiologist and the urologist.
AI-Rad Companion Organs RT1 – your aide for radiation therapy planning
AI-Rad Companion Organs RT automatically contours several organs at risk. This input can be used for further processing in a treatment planning system. This enables physicians to free up resources for other time-consuming tasks and drives standardization across different individuals and institutions.
How customers use AI-Rad Companion
Customers around the world are using AI-Rad Companion in their clinical routine. Learn how they benefit since they started using AI-Rad Companion Chest CT in their daily work.
AI-Rad Companion may help you to increase precision and speed up your workflow
We developed the AI-Rad Companion to help you cope with a growing workload. With its deep learning algorithms, AI-Rad Companion automatically highlights abnormalities, segments anatomies, and compares results to reference values.
Discover how AI-Rad Companion supports you as a full-time radiology expert
The AI-Rad Companion Chest CT detects and highlights lung nodules. After segmentation of the lung nodules, the volume, maximum 2D diameter, maximum 3D diameter and tumor burden are automatically calculated.
Courtesy of Klinikum Nürnberg, Nuremberg, Germany
Smooth integration of artificial intelligence into the radiology environment
Drive productivity with seamless integration in the reading and reporting workflow includingautomated measurements and DICOM structured reports ̶ while every workflow step remains under control to enable evidence based decisions.
The entire global population has been impacted, in one way or another, by the COVID-19 virus. The AI-Rad Companion, our Siemens Healthineers AI driven solution, offers our customers the opportunity to have access to different postprocessing software for the analysis of lung examinations.
AI-Rad Companion Chest CT Pneumonia Analysis3
The algorithm is designed to automatically identify and quantify abnormal tomographic patterns in the lungs from chest CT for research purposes. The system takes as input a non-contrasted chest CT, identifies and 3D segments the lungs and lobes before segmenting the abnormalities. It outputs two combined measures of the severity of lung/lobe involvement, quantifying both the extent of COVID-19 abnormalities and presence of high opacities. High opacity abnormalities were shown to correlate with severe symptoms. The first disease severity measure is global, while the second is lobe-wise.
First global measure:
- Percentage of Opacity (PO): Percentage of predicted volume of abnormalities compared to the total lung volume
- Percentage of High Opacity (PHO): Percentage of predicted high opacity volume compared to the predicted volume of abnormalities
Second lobe-wise measure:
- Lung Severity Score (LSS): The extent of abnormalities across each lobe
- Lung High Opacity Score (LHOS): The extent of high opacity abnormalities for each lobe
The computed results could be used to analyze the severity and monitor the progression of abnormalities in patients exhibiting COVID-19 symptoms.
The performance of the method in estimating PO, LSS, PHO, and LHOS is evaluated on a database of 100 COVID-19 cases and 100 controls from multiple institutions from Canada, Europe, and the U.S. Ground truth is established by computing the same measures from manual annotations of the lesions, lungs, and lobes.
AI-Rad Companion Research Chest X-ray Pneumonia Analysis4
This prototype is designed to automatically identify and quantify airspace opacities of the lung, enabling simple to use analysis of chest X-rays for research purposes only (not for clinical use). AI-Rad Companion Research Chest X-ray Pneumonia Analysis will perform automated lung opacity analysis on Chest X-ray (AP or PA viewing direction), highlighting identified regions. Other radiographical findings, such as pneumothorax, pulmonary lesions, atelectasis, consolidation and pleural effusion are included as well.
AI-Rad Companion Chest X-ray2
Chest imaging, X-ray in particular, plays an important role in patient management during the COVID-19 pandemic5. Patient management and clinical decisions depend on clinical outcomes and imaging reports. The new member of the AI-Rad Companion family, the AI-Rad Companion Chest X-ray, automatically processes upright chest X-ray images (PA direction). Next to pneumothorax, pleural effusion and nodule detection, the AI-Rad Companion Chest X-ray is able to indicate consolidations and atelectasis. The latter may be signs of pneumonia caused by the COVID-19 virus.
AI-Rad Companion Brain MR, Chest CT, Prostate MR and Organs RT are not yet commercially available in all countries and their future availability cannot be ensured.
AI-Rad Companion Chest X-ray is currently under development; it is not for sale in the United States and other countries. CE mark is available.
The pulmonary density functionality is not commercially available in all countries, and its future availability cannot be ensured. As soon as this functionality is available and cleared for your country it will become entitled to your institution.
The Pulmonary Density feature is new in VA12A without FDA Clearance. According to FDA policy “Enforcement Policy for Imaging Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency” issued in April 2020, the manufacturer is allowed to market this feature without FDA-clearance. This policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19 declared by the HHS, including any renewals made by the HHS Secretary in accordance with section 319(a)(2) of the Public Health Services Act (42 U.S.C. 247d(a)(2)). Pulmonary Density results are not indicated for the diagnosis of COVID-19. Only in vitro diagnostic testing is currently the definitive method to diagnose COVID-19.
For research purpose only. Not for clinical use. This prototype is still under development and not yet commercially available. Its future availability cannot be ensured.